文献速递艾滋病与性传播感染病毒性肝炎

直接抗病毒方案获得持续病毒学应答降低HIV/HCV合并感染肝硬化患者的肝细胞癌风险

Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

这项多中心前瞻性队列研究纳入495例新诊断代偿期肝硬化的HIV/HCV合并感染患者,随访至肝细胞癌、死亡或2017年3月截尾。全口服DAA方案获得SVR与肝细胞癌风险降低独立相关(亚风险比0.264,95%CI 0.070-0.991,P=0.049)。

要点

  • 495例HIV/HCV合并感染肝硬化患者中,中位随访59个月有22例(4.4%)发生肝细胞癌。
  • 全口服DAA后肝细胞癌发生率0.35/100人年,其余队列为1.79/100人年(P=0.0005)。
  • 随访期间全口服DAA获得SVR与肝细胞癌风险降低独立相关(亚风险比0.264,95%CI 0.070-0.991,P=0.049)。

核心结论

  • 全口服DAA方案获得SVR可降低HIV/HCV合并感染代偿期肝硬化患者的肝细胞癌风险。

研究设计与样本

  • 多中心前瞻性队列研究,纳入新诊断代偿期肝硬化的HIV/HCV合并感染患者,随访至肝细胞癌、死亡或2017年3月截尾,共495例。

主要发现

  • 中位随访59个月(IQR 27-84)期间,22例(4.4%;95%CI 2.6-6.3)发生肝细胞癌,肝细胞癌发生率为0.93(95%CI 0.06-1.42)/100人年。
  • 随访期间303例(61%)获得SVR,其中79例经干扰素为基础方案、224例经全口服DAA方案。
  • 全口服DAA后肝细胞癌发生率0.35(95%CI 0.14-0.85)/100人年,其余队列为1.79(95%CI 1.11-2.88)/100人年(P=0.0005)。
  • 仅考虑获得SVR的患者,全口服DAA后肝细胞癌发生率为0.32(95%CI 0.12-0.86)/100人年,干扰素为基础方案获得SVR者为0/100人年(P=0.27)。
  • 随访期间全口服DAA获得SVR与肝细胞癌发生风险降低独立相关(亚风险比0.264;95%CI 0.070-0.991;P=0.049)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of all-oral direct-acting antiviral agent (DAA) regimens on the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients with cirrhosis. METHODS: This was a multicentre prospective cohort study recruiting HIV/HCV-coinfected patients with a new diagnosis of compensated cirrhosis. Patients were followed up until HCC, death or the censoring date (March 2017). The primary endpoint was the emergence of HCC. The incidence rate (IR) (95% CI) of HCC in different groups was computed. Time-to-event analyses were performed to identify predictors of HCC emergence. RESULTS: The study included 495 HIV/HCV-coinfected patients with cirrhosis. After a median (IQR) follow-up of 59 (27-84) months, 22 (4.4%; 95% CI 2.6-6.3) patients developed an HCC. The IR (95% CI) of HCC was 0.93 (0.06-1.42) per 100 person-years (PY). Three hundred and three (61%) patients achieved sustained virological response (SVR) during follow-up, 79 after interferon (IFN)-based regimens and 224 after an all-oral DAA regimen. The IR (95% CI) of HCC after all-oral DAA was 0.35 (0.14-0.85) per 100 PY whereas it was 1.79 (1.11-2.88) per 100 PY in the remaining cohort (P = 0.0005). When only patients with SVR were considered, the IR (95% CI) of HCC after all-oral DAA was 0.32 (0.12-0.86) whereas it was 0 per 100 PY among those with SVR after IFN-based therapies (P = 0.27). Achieving SVR with an all-oral DAA regimen during follow-up was independently associated with a lower risk of HCC emergence (subhazard ratio 0.264; 95% CI 0.070-0.991; P = 0.049). CONCLUSIONS: SVR with all-oral DAA regimens reduces the risk of HCC in HIV/HCV-coinfected patients with compensated cirrhosis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Merchante N, Rivero-Juárez A, Téllez F, et al. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother. 2018. PMID: 29982683. doi:10.1093/jac/dky234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。